Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research

1. Ipsen, a global specialty-driven biopharmaceutical group, has entered into a strategic partnership with Skyhawk Therapeutics, a biotechnology company specializing in RNA modulation.

2. The collaboration aims to advance the discovery and development of novel RNA modulator therapies for various diseases, with a focus on neurological conditions and cancer.

3. The deal is valued at up to $1.8 billion, including an upfront payment, equity investment, and potential milestone payments and royalties.

4. Skyhawk Therapeutics will utilize its proprietary SkySTAR™ technology platform to identify and validate RNA modulator targets, while Ipsen will contribute its expertise in drug development and commercialization.

5. The partnership will initially focus on three undisclosed targets, with the potential to expand to additional targets in the future.

6. This collaboration marks a significant step for Ipsen in expanding its R&D capabilities and diversifying its therapeutic portfolio.

7. For Skyhawk Therapeutics, the partnership provides additional resources and validation for its RNA modulator technology, further establishing its position in the field of RNA therapeutics.